Compare Gilead Sciences, Inc. (GILD) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kraft Heinz Co — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while Kraft Heinz Co trades at $24.7 (market cap $29.56B). The key difference: Gilead Sciences, Inc. is far larger — about 5.6× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.42%). Which is the better fit depends on your goals.
| GILD | KHC | |
|---|---|---|
Market Cap | $164.99B | $29.56B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $28.06 |
52-Week Low | $110.56 | $21.21 |
Enterprise Value | $188.06B | $45.88B |
Dividend Yield | 2.47% | 6.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
Kraft Heinz (KHC) trades at $25.32, up 1.44% today, with a bearish technical signal but oversold RSI. The stock shows mixed fundamentals: earnings beat estimates in recent quarters, yet 2025 net income was -$5.85B, reflecting margin pressures. Revenue declined to $24.94B in 2025, while the P/E of 13.04 and P/B of 0.83 suggest undervaluation. Recent news highlights CEO Cahillane's strategy to boost marketing spend for growth, amid institutional selling by firms like Bank of America (Defense World, 2026-08-09).
Outlook remains cautious; the 6% dividend yield attracts income investors, but sustainability is questioned amid profit declines. Risks include persistent inflation and competitive headwinds. Analysts are mostly neutral (57.14% Hold), with a $24 consensus target, implying limited upside. The stock's trajectory hinges on successful execution of turnaround efforts to stabilize earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
